Pay in 4 interest-free payments of $6.57 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
In vitro activity of ibrexafungerp against a collection of clinical isolates of aspergillus, including cryptic species and cyp51A mutants, using EUCAST and CLSI methodologies
Most patients tolerate GLP-1 medications well, and with appropriate management strategies, side effects can usually be minimised whilst maintaining the significant metabolic benefits these medications provide
General indications for both drug classes include adults with type 2 diabetes who have inadequate glycaemic control despite lifestyle modifications and first-line therapy with metformin
Interactions CYP: In vivo, one study reported increased or decreased expression of different isoforms (Olsozowy 2006)
US$ 29.93
US$ 24.52
US$ 27.63
US$ 28.89
